
    
      This is a prospective, multi-center, randomized and controlled study. Advanced lung cancer
      patients without venous thromboembolism(VTE) are included. The selected patients were
      randomized into A and B groups. Group A: Nadroparin given during hospitalization, 0.4mL,
      subcutaneously, qid; Group B: Nadroparin given by long-term, 0.4mL, subcutaneously, qid. The
      incidence of VTE , the risks of bleeding and overall survival in two groups of patients are
      studied at different time points.
    
  